Humacyte reported second quarter 2026 results showing commercial sales of Symvess increased to $0.4 million from $0.1 million in the prior year period. The company announced breakthrough Phase 3 data for its ATEV dialysis access product, where it outperformed AV fistula in female patients, and plans to file a supplemental Biologics License Application with the FDA later this year. Additionally, the FDA accepted an IND application for CTEV, initiating a Phase 2a study for coronary artery bypass grafting expected in Q3 2026. Humacyte raised $57.5 million via public offering in June and implemented workforce reductions estimated to save $14.3 million annually. The company operates as a commercial-stage biotechnology platform developing bioengineered human tissues.

Humacyte, Inc. received a notification from Nasdaq on July 31, 2026, that its common stock failed to maintain the minimum $1.00 bid price requirement for 30 consecutive business days ending July 30, 2026. The company has been granted an initial compliance period of 180 calendar days, expiring on January 27, 2027, during which it must restore the closing bid price to at least $1.00 for a minimum of 10 consecutive business days. This notice does not immediately affect the listing or trading of HUMA shares on the Nasdaq Global Select Market, nor does it impact business operations. The company intends to monitor its stock price and consider options to regain compliance but cannot assure success. Humacyte, Inc. operates in the biotechnology industry, specializing in the development of human hemoglobin-based oxygen carriers.

Humacyte, Inc. entered into an underwriting agreement with Barclays Capital Inc., BTIG, LLC, and Titan Partners Group LLC to issue and sell 47,619,048 shares of common stock at $1.05 per share. The company expects to receive net proceeds of approximately $46.80 million, or approximately $53.85 million if the underwriters' 30-day option to purchase an additional 7,142,857 shares is exercised in full. The offering is expected to close on or about June 12, 2026. Humacyte, Inc. is a biotechnology company developing human-made tissue engineering products.

Humacyte, Inc. announced the presentation of Phase 3 clinical trial (V012) results for its acellular tissue engineered vessel (ATEV) in arteriovenous access for female patients with end-stage renal disease. The company also released an investor presentation. Humacyte, Inc. is a biotechnology company developing tissue engineered medical products.

At its 2026 Annual Meeting of Stockholders on June 9, 2026, Humacyte, Inc. stockholders approved an amendment to the Certificate of Incorporation to increase the number of authorized shares of common stock from 350,000,000 to 550,000,000. The meeting also resulted in the election of three Class II directors and the following advisory votes: approval of executive compensation on an advisory basis, approval of annual frequency for future advisory votes on executive compensation, annual ratification of ratification of Pricewaterhouse Coopers LLP as the company's independent registered public accounting firm. Humacyte, Inc. is a biotechnology company that develops human-derived tissue-engineered products.